Bryony Dawkins


Following the completion of my MSc in Health Economics, I joined the Academic Unit of Health Economics as a Research Assistant in 2015. In 2017, I was appointed as Research Fellow in Health Economics.

Research interests

My research interests include economic modelling, global health, health equity and inequalities in health and healthcare.

Current and recent research projects include:

  • GHRG-ST: Global Health Research Group - Surgical technologies:
    • FIXT: Feasibility of Ilizarov frame fiXation for closed Tibial fractures in Sierra Leone
    • TARGET: Training programme in gAsless lapaRoscopic surGery for rural surgEons of NorTh-East India
  • Acupuncture Neuropathy (Hong Kong): A randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy (Hong Kong)
  • REACH: feasibility trial: Research Exploring physical Activity in Care Homes
  • Lots2Care - A longer-term care strategy to support stroke survivors and their carers (LoTS2Care) – Feasibility study
  • FitNEsS (Myeloma XIV): Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Symptomatic Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRDa) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I)
  • COMDIS-HSD: A pragmatic cluster randomised controlled trial for reducing irrational antibiotic prescribing among children with upper respiratory infections in rural China
  • COMDIS-HSD: Enhanced diabetes-cardiovascular management through primary healthcare in Pakistan: a cluster randomised trial
  • White Rose Collaboration project: Assessing the appropriateness of existing model adaption methods to the context of middle income countries: a case study on Taxanes for adjuvant treatment of early breast cancer in South Africa
  • eRAPID: Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice 
  • TEAMM: Tackling Early Morbidity and Mortality in Myeloma
  • MUK Eight: A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib (ICD), in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and bortezomib
  • SWITCH: randomised-controlled trial of switching to alternative tumour-necrosis factor (TNF)-blocking drugs or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-blocking drug


  • MSc Health Economics - University of York
  • BA (Hons) Economics and History - University of Leeds

Research groups and institutes

  • Leeds Institute of Health Sciences
  • Health economics
  • Academic Unit of Health Economics
  • Decision Modelling Group
  • Applied Health Econometrics Group
  • International health research